WC
CATX icon

Wexford Capital’s Perspective Therapeutics CATX Stock Holding History

Wexford Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100,000
Closed -$213K – 256
2025
Q1 		$213K Buy
100,000
+80,000
+400% +$240K 0.06% 181
2024
Q4 		$63.8K Buy
+20,000
New +$163K 0.01% 202

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wexford Capital's CATX Position: Q2 2025 in Review

Wexford Capital sold out of Perspective Therapeutics (CATX) in Q2 2025, closing a stake of 100,000 shares — an estimated $213K sold.

Wexford Capital first reported a position in CATX in Q4 2024 and held it in 2 quarters. The position peaked at $213K in Q1 2025. 97 funds tracked by Wall St. Rank hold CATX as of Q2 2025.

  • Wexford Capital reported no remaining Perspective Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wexford Capital sold 100,000 Perspective Therapeutics shares in Q2 2025, an estimated $213K.
  • Wexford Capital first reported a position in Perspective Therapeutics in Q4 2024 and held it in 2 quarters.
  • Wexford Capital's Perspective Therapeutics position peaked at $213K in Q1 2025.
  • 97 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2025.

Based on Wexford Capital's 13F filing for Q2 2025, filed 14 Aug 2025.